Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- R&D NEWS IN BRIEF
January 26, 2009
- Kyowa Kirin to Develop KW-6002 in Japan by Itself, License It Out Overseas
January 26, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 26, 2009
- REGULATORY NEWS IN BRIEF
January 26, 2009
- Ranbaxy to Join Daiichi Sankyo to Market Olmesartan in India
January 26, 2009
- Novartis to Start Global PIII Trial of Everolimus for Stomach Cancer Based on POC Established in Japan
January 26, 2009
- Taisho Ties Up with GSK to Commercialize Xenical in Japan
January 26, 2009
- Biosimilars Are Likely to Be Developed by Research-Driven Companies in Japan: Ihoken
January 26, 2009
- Korosho to Draw Conclusion on Drug Pricing System Reform in 2009: Mr Kinoshita
January 26, 2009
- Inhibition of BDNF by Stress Hormones Shown by NCNP/NIN Research Team
January 26, 2009
- CMIC Aims at Launching Human Hemin in 2011
January 19, 2009
- J-TEC's Jace Becomes Available under Health Insurance
January 19, 2009
- JPMA to Place Top Priority on NHI Drug Pricing System Reform in 2009: Mr Shoda
January 19, 2009
- MHIR Develops Software to Predict Secondary RNA Structures
January 19, 2009
- Bayer Schering Licenses PET Tracers from Hamamatsu Photonics
January 19, 2009
- Korosho to Talk with NCVC on Evaheart Issue
January 19, 2009
- Sales of Generics Top ¥10 Bil. at Meiji Seika
January 19, 2009
- Team of 16 Organizations Aims at Developing Artificial Joints Durable for 30 Years
January 19, 2009
- R&D of Micellar Anticancer Drugs Progresses at Nippon Kayaku
January 19, 2009
- Sato Pharm Launches Thyrogen to Aid in Thyroid Cancer Diagnosis
January 19, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…